Sandoz Mobile Health Initiative: Empowering Communities Through Accessible Care

By João L. Carapinha

May 5, 2026

Sandoz mobile health initiative

Sandoz has launched the Sandoz mobile health initiative in Portugal through its “Sandoz em Marcha” project, sending a mobile health unit to 16 localities over two months to deliver free screenings and health education while strengthening the role of community pharmacies as everyday access points.

Direct Community Screenings Roll Out

The unit provides cardiovascular risk checks plus metabolic, respiratory, venous, digestive, bone and skin assessments with rapid tests, followed by personalized counseling and medical referrals when needed. An accredited pharmacist training program pairs classroom learning with on-site practice, building professional skills while capturing real data on local health needs. These combined services within the Sandoz mobile health initiative target chronic disease burdens, low health literacy and uneven access to care.

Proven Model Expanded from Spain

After successful runs in Madrid and Catalonia, the Portuguese Sandoz mobile health initiative works with pharmacy groups, municipalities, patient associations and media partners to embed the mobile unit in daily community life. The unit functions as both a clinical outpost and an awareness platform, positioning pharmacies as continuous partners in prevention rather than simple dispensaries.

Data Driving Better Access Strategies

Usage figures, detected risk cases and patient feedback from the Sandoz mobile health initiative supply practical inputs for health economics evaluations of community-based prevention. Strengthened pharmacist involvement in early detection and adherence support offers evidence that can shape future reimbursement discussions and highlight how manufacturers can deliver value beyond medicines alone.

Reference url

Recent Posts

Perioperative Bladder Cancer Therapy
Advancements in Perioperative Bladder Cancer Therapy: A Promising New Regimen

By João L. Carapinha

May 25, 2026

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of KEYTRUDA (pembrolizumab), including its subcutaneous formulation KEYTRUDA SC, combined with Padcev (enfortumab vedotin-ejfv) as neoadjuvant treatment followed b...
Hepcludex HDV approval
Hepcludex HDV Approval: A Breakthrough in Chronic Hepatitis Delta Treatment
The U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. This Hepcludex HDV approval addresses a previously unmet need for patients faci...
CHMP recommendations 2026
CHMP Recommendations 2026: New Approvals and Implications for Health Economics
The CHMP recommendations 2026 from the 18–21 May meeting delivered eight positive opinions for new medicines, thirteen extensions of therapeutic indications, and one negative opinion. These decisions bring meaningful progress in areas with significant unmet need, most notably idiopathic pulmonary...